Need professional-grade analysis? Visit stockanalysis.com
$284.98M
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
Palisade Bio Inc (PALI) Price Performance
Palisade Bio Inc (PALI) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $2.00, up 5.82% from the previous close.
Over the past year, PALI has traded between a low of $0.54 and a high of $2.50. The stock has gained 185.7% over this period. It is currently 20.0% below its 52-week high.
Palisade Bio Inc has a market capitalization of $284.98M.
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Company Info
- Sector
- Healthcare
- Industry
- Biological Products
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- N/A
- EBITDA
- $-18,053,000
- Profit Margin
- N/A
- EPS (TTM)
- -0.30
- Book Value
- 0.81
Technical Indicators
- 52 Week High
- $2.64
- 52 Week Low
- $0.53
- 50 Day MA
- $1.80
- 200 Day MA
- $1.38
- Beta
- N/A
Valuation
- Trailing P/E
- N/A
- Forward P/E
- -7.12
- Price/Sales
- N/A
- Price/Book
- 2.36
- Enterprise Value
- $183.53M